<- Go Home
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Market Cap
$77.8M
Volume
84.6K
Cash and Equivalents
$1.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.15
52 Week Low
$0.73
Dividend
N/A
Price / Book Value
-8.06
Price / Earnings
-5.71
Price / Tangible Book Value
-8.06
Enterprise Value
$76.2M
Enterprise Value / EBITDA
N/A
Operating Income
-$13.5M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$1.6M
Debt
N/A
Equity
-$9.8M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A